NEW ORLEANS -- Evolocumab (Repatha) reduced risk of a first major cardiovascular (CV) event in patients with diabetes but no known atherosclerosis in a substudy of the VESALIUS-CV trial. The PCSK9 ...

Lerodalcibep, a novel, third-generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, reduced low-density lipoprotein cholesterol (LDL-C) by more than 50% after 1 year in patients ...

NEW ORLEANS — The first global randomized trial of the PCSK9 inhibitor evolocumab for the prevention of a primary major adverse cardiovascular event (MACE) found a relative reduction in risk similar ...

Add Yahoo as a preferred source to see more of our stories on Google. This year at the American Diabetes Association (ADA) Scientific Sessions, new Phase III data were presented evaluating the safety ...

Strong preclinical evidence suggested PCSK9 inhibitors may overcome immunotherapy resistance by preventing tumor cells from evading the immune system. In patients with lung cancer, melanoma, or kidney ...

Immune checkpoint therapy, particularly anti-PD-1/PD-L1 immunotherapy, have achieved significant results in the treatment of various tumors. However, most cancer patients show a low response rate to ...

Please provide your email address to receive an email when new articles are posted on . PCSK9 inhibition demonstrated benefit in the broader primary prevention population for LDL lowering and plaque ...

Enlicitide, an oral PCSK9 inhibitor, reduced LDL-C by nearly 60% in adults with or at risk for ASCVD. The medication offers a daily oral alternative to injectable PCSK9 inhibitors, potentially ...

Please provide your email address to receive an email when new articles are posted on . PCSK9 inhibitor prescriptions are rejected by insurers at a higher rate vs. other guideline-indicated ...

Use of a PCSK9 inhibitor to lower lipid levels was linked with significantly better survival in patients with certain cancers treated with immune checkpoint inhibitors (ICIs), a matched-cohort study ...